This course is still available as a learning tool but has expired for CME credit.
A substantial proportion of the rheumatoid arthritis patient population is not only unresponsive to therapy but experiences an unsustained response to treatment. The management of RA actively evolves as further evidence-based data becomes available. This program is designed to improve the educational command of immunology science and how it is shaping the relatively recent development of biologics and DMARDS. Expert rheumatologists will discuss challenges involved in individualizing treatment plans that include appropriate patient selection, combination therapies, sequencing of therapies, and assessing comorbidities. This CME program will provide rheumatologists and other health care professionals a current understanding of care and treatment strategies for the RA patient.
This activity was designed to meet the needs of rheumatologists, immunologists, primary care practitioners and other healthcare professionals who care for patients with rheumatoid arthritis.
- Explain the current basis of immunopathology in rheumatoid arthritis and how this is shaping the development of therapies.
- Review the current clinical trial data and modes of action of available DMARD and biologic therapeutics
- Develop individualized treatment plans that include patient selection, combination therapies, and sequencing of therapies.
- Assess strategies to manage comorbidities in patients with rheumatoid arthritis